



(12) Translation of
European patent specification

(11) NO/EP 3196202 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 487/04 (2006.01)
A61K 31/519 (2006.01)
A61P 1/00 (2006.01)
A61P 17/00 (2006.01)
A61P 19/00 (2006.01)
A61P 27/00 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.07.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.02.27
(86)	European Application Nr.	16199883.6
(86)	European Filing Date	2012.08.31
(87)	The European Application's Publication Date	2017.07.26
(30)	Priority	2011.09.02, US, 201161530866 P 2012.02.03, US, 201261594882 P 2012.07.30, US, 201261677445 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA; ME
(62)	Divided application	EP2751109, 2012.08.31
(73)	Proprietor	Incyte Holdings Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA
(72)	Inventor	LI,, Yun-Long, 1 Pin Oak Drive, Chadds Ford, PA Pennsylvania 19317, USA YAO,, Wenqing, 748 Meadowbank Road, Kennett Square, PA Pennsylvania 19348, USA COMBS,, Andrew, P., 329 East Doe Run Road, Kennett Square, PA Pennsylvania 19348, USA YUE,, Eddy, W., 9 Altemus Drive, Landenberg, PA Pennsylvania 19350, USA MEI,, Song, 151 Monet Circle, Wilmington, DE Delaware 19808, USA ZHU, Wenyu, 30 Diemer Drive, Media, PA 19063, USA GLENN,, Joseph, 103 Deer Horn Drive, Mount Royal, NJ New Jersey 08061, USA MADUSKUIE,, Thomas, P., Jr., 613 Foulkstone Road, Wilmington, DE Delaware 19803, USA SPARKS,, Richard, B., 3316 Englewood Road, Wilmington, DE Delaware 19810, USA

DOUTY,, Brent, 3420 Strasburg Road East, Fallowfield, PA Pennsylvania 19320, USA

HE,, Chunhong, 40 Magnolia Way, Chadds Ford, PA Pennsylvania 19317, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge

(54) Title **HETEROCYCLYLAMINES AS PI3K INHIBITORS**

(56) References

Cited:

WO-A1-2007/042806

WO-A1-2010/036380

S. J. SHUTTLEWORTH ET AL: "Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors", CURRENT MEDICINAL CHEMISTRY, vol. 18, no. 18, 1 June 2011 (2011-06-01), pages 2686-2714, XP055019800, ISSN: 0929-8673, DOI: 10.2174/092986711796011229

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Krav

1. Forbindelse som er valgt fra:

5 (5R)-{3-[1-(R)-(4-amino-3-metyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-
5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-2-on;
(5R)-{3-[1-(S)-(4-amino-3-metyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-
5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-2-on;
(5S)-{3-[1-(R)-(4-amino-3-metyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-
5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-2-on; og
10 (5S)-{3-[1-(S)-(4-amino-3-metyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-
5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-2-on;

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1, som er (5R)-{3-[1-(R)-(4-amino-3-metyl-1H-
pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-
15 2-on, eller et farmasøytisk akseptabelt salt derav.

3. Forbindelse ifølge krav 1, som er (5R)-{3-[1-(S)-(4-amino-3-metyl-1H-
pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-
2-on, eller et farmasøytisk akseptabelt salt derav.
20

4. Forbindelse ifølge krav 1, som er (5S)-{3-[1-(R)-(4-amino-3-metyl-1H-
pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-
2-on, eller et farmasøytisk akseptabelt salt derav.

- 25 5. Forbindelse ifølge krav 1, som er (5S)-{3-[1-(S)-(4-amino-3-metyl-1H-
pyrazolo[3,4-d]pyrimidin-1-yl)etyl]-5-klor-2-etoksy-6-fluorfenyl}-1,3-oksazolidin-
2-on, eller et farmasøytisk akseptabelt salt derav.

6. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket
30 som helst av kravene 1 til 5, eller et farmasøytisk akseptabelt salt derav og minst
en farmasøytisk akseptabel bærer.